Paroxetine Associated Hepatotoxicity: A Report of 3 Cases and a Review of the Literature

We recently encountered 3 patients who had developed reversible paroxetine-associated hepatotoxicity. Two of the patients were over 80 years old and their hepatitis was accompanied by hyponatremia. In the third case, hepatitis was associated with multiple organ failure and the co-administration of trazodone. Here, we will discuss the possible role of preexisting risk factors in the development of paroxetine hepatotoxicity and review the relevant literature.

References

• 1 Beck P L, Bridges R J, Demetrick  D J. et al . Chronic active hepatitis associated with trazodone therapy.  Ann Intern Med. 1993;  118 10-16
• 2 Benbow S J, Gill G. Paroxetine and hepatotoxicity.  BMJ. 1997;  314 s1387
• 3 Boyer W F, Blumhardt C L. The safety profile of paroxetine.  J Clin Psychiatry. 1992;  53 (6) 61-66
• 4 Brogden R N, Heel R C. et al . Trazodone: review pharmacological properties and therapeutic use in depression and anxiety Drugs.  . 1981;  21 401-429
• 5 Brondeau M T, Ban M, Bonnet P, Guenier J, De Ceaurriz J. Concentration-related changes in blood and tissue parameters of hepatotoxicity and their interdependence in rats exposed to bromobenzene and 1,2-dichlorobenzene.  Toxicol Lett. 1986;  31 (2) 159-166
• 6 Cadranel J F, Martino V, Cozier A. et al . Atrium and paroxetine-related severe hepatitis.  J Clin Gastroenterol. 1999;  28 52-55
• 7 Chu A G, Gansolly B L, Summers R W. et al . Chronic active hepatitis associated with trazodone therapy.  Ann Intern Med. 1983;  99 128-129
• 8 Doyle G D, Laher M, Kelly J G. et al . The pharmacokinetics of paroxetine in renal impairment.  Acta Psychiatr Scand. 1989;  80 (350) 89-90
• 9 Dunbar G C, Claghorn J L, Kiev A. et al . A comparison of paroxetine and placebo in depressed patients.  Acta Psychiatr Scand. 1993;  87 302-305
• 10 Fenichel R R. Drug-induced hepatotoxicity.  N Engl J Med. 1996;  334 (13) 864
• 11 Helmchen C, Boerner R J, Meyendorf R. et al . Reversible Hepatotoxicity of paroxetine in a patient with major depression.  Pharmacopsychiatry. 1996;  29 223-226
• 12 Hiemke C, Hartler S. Pharmacokinetics of selective serotonin reuptake inhibitors.  Pharmacol Ther. 2000;  85 (1) 11-28
• 13 Horsmans Y, Lannes D, Pessayre D, Larrey D. Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate.  J Hepatol. 1994;  21 (6) 1075-1079
• 14 Kaye C M, Haddock R E, Langley P F. et al . A review of the metabolism and pharmacokinetics of paroxetine in man.  Acta Psychiatr Scand. 1989;  80 (350) 60-75
• 15 Kuhs H, Rudolf G AE. A double-blind study of the comparative antidepressant effect of paroxetine and amitriptyline.  Acta Psychiatr Scand. 1989;  80 (350) 89-90
• 16 Larrey D, Pageaux G P. Genetic predisposition to drug-induced hepatotoxicity.  J Hepatol. 1997;  26 (2) 12-21
• 17 Longstreth G F, Hershman J. Trazodone-induced hepatotoxicity and leukonychia.  J Amer Acad Dermatol. 1985;  13 149-150
• 18 Man R A. Severe hepatitis attributed to paroxetine. In Dutch.  Ner Tijdschr Geneeskd. 1997;  141 (11) 540-542
• 19 Mann S C, Walker M M, Messenger G G, Greenstein R A. Leukocytoclastic vasculitis secondary to trazodone treatment.  J Am Acad Dermatol. 1984;  10 (4) 669-670
• 20 Meynaar I A, Peelers A J, Mulder A H. et al . Syndrome of inappropriate ADH secretion attributed to the serotonin re-uptake inhibitors, venlafaxine and paroxetine.  Neth J Med. 1997;  50 243-245
• 21 Rasmussen B B, Brossen K. Is therpeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors.  Ther Drug Monit. 2000;  22 (2) 143-154
• 22 Rickels K, Amsterdam J, Clary C. et al . A placebo-controlled, double blind clinical trial of paroxetine in depressed outpatients.  Acta Psychiatr Scand. 1989;  80 (350) 117-123
• 23 Schatzberg A F. New indications for antidepressants.  J Clin Psychiatry. 2000;  61 (11) 9-17